CALGB

加州大学伯克利分校

• 批准号: 2601240
• 负责人: MICHAEL R GREVER
• 金额: $ 19.45万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-16 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2601240
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This is a multi-disciplinary collaborative research project for the development of more effective methods of prevention, detection, and treatment of human cancer in all its forms. This research focuses the efforts of medical oncologists, surgeons, radiotherapists, psychiatrists, pathologists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk for its development. Included in this project are the following: (1) the exploration of new therapeutic agents, and their associated toxicities, through a wide range of neoplastic diseases in Phase I, II, and III studies; (2) the evaluation of the efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; (3) the development of multi-modal approaches to specific tumor problems using surgical, immunological, and radiotherapeutic measures in optimal combinations; (4) the involvement of pertinent basic science disciplines such as biochemistry, pharmacology, cellular biology, and mathematics in the formulation and execution of specific treatment protocols; (5) the improvement of cancer care in the community by using these programs in the educational effort directed at pre- and postdoctoral students, nurses, allied medical personnel and physicians; (6) the evaluation of biologic studies in correlation with clinical endpoints so as to build toward more rationally, based cancer management; (7) the evaluation of cancer control efforts such as early detection; and (8) the study of the psycho-social aspects of cancer. This application for permanent membership in the Cancer and Leukemia Group B represents a turning point in the cooperative group clinical research activities of The Ohio State University as it leaves its long-standing affiliation with the Southwest Oncology Group. Motivating this change is the recruitment of Drs. Clara D. Bloomfield, Michael A. Caligiuri, and Albert de la Chapelle. The research attributes of these outstanding investigators are synergistic with existing capabilities at Ohio State. Combining these separate strengths will enhance development of innovative clinical trials especially those with basic science correlates and strengthen Ohio State's cancer cooperative group participation.

描述（改编自申请人的摘要）：这是一个 多学科合作研究项目的发展 更有效的方法来预防、检测和治疗人类 各种形式的癌症。 这项研究的重点是医学界的努力 肿瘤科医生、外科医生、放射治疗师、精神科医生、病理学家、基础 科学家、统计学家、流行病学家、护士、药剂师和 临床研究助理进行精心设计和进行的研究，询问 相互关联的临床和基础科学问题，其答案有助于 对患者护理和减少人群中癌症的发生具有重要意义 其发展风险增加。 该项目包括 (1)新治疗药物的探索及其 相关毒性，通过阶段广泛的肿瘤疾病 I、II 和 III 研究； (2)药效和毒性评价 新的治疗方案，包括新旧药物的组合，以努力 更有效地利用协同组合； (3)发展 使用手术的多模式方法来解决特定的肿瘤问题， 免疫学和放射治疗措施的最佳组合； (4) 相关基础科学学科的参与，例如生物化学， 制剂和制剂中的药理学、细胞生物学和数学 执行具体治疗方案； (5)癌症的改善 通过在教育工作中使用这些计划来提供社区护理 针对博士前和博士后学生、护士、相关医务人员 和医生； (6) 相关生物学研究的评价 临床终点，以便建立更合理、有基础的癌症 管理; (7) 早期癌症控制工作的评估 检测； (8)癌症心理社会方面的研究。 这 申请成为癌症和白血病 B 组永久成员 代表了合作组临床研究的转折点 俄亥俄州立大学的活动，因为它离开了它的长期存在 隶属于西南肿瘤学组。 推动这一变化的是 博士的招募。克拉拉·D·布卢姆菲尔德 (Clara D. Bloomfield)、迈克尔·A·卡利朱里 (Michael A. Caligiuri) 和 阿尔伯特·德拉·夏贝尔。 这些杰出人物的研究属性 调查人员与俄亥俄州立大学的现有能力具有协同作用。 结合这些各自的优势将促进创新的发展 临床试验，尤其是那些与基础科学相关的临床试验 加强俄亥俄州立大学癌症合作小组的参与。